Green industry professionals and others interested in biological control and sustainable pest solutions can learn about the latest recommendations and best practices by attending an upcoming ...

The U.S. FDA has accepted a Biologics License Application (BLA) for BAT2506, a proposed biosimilar to Simponi (golimumab).

Over the first weeks of July 2025, the U.S. Food and Drug Administration (FDA) has issued several announcements heralding new policies and ...

Ultragenyx Pharmaceuticals RARE announced that the FDA has issued a Complete Response Letter (CRL) for its biologics license ...

Nanoscope Therapeutics submitted the first modules of a biologics license application for MCO-010, an investigational gene ...

Shares of Capricor Therapeutics CAPR tanked 33% on Friday after it announced that the FDA issued a complete response letter ( ...

What Should Capricor Therapeutics, Inc. Investors Do? If you invested in Capricor Therapeutics, Inc., visit our Capricor Terapeutics, Inc. Investigation webpage or call us at (888) 410-2925 to get ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the ...

Pennsylvania offers 140 elk hunting licenses for the 2025-2026 seasons. The application deadline is July 13, with the drawing on July 26 at the Elk Expo. Hunters achieved high success rates in ...

RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease.

These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.